Science Explorer Back to mapMap
Discussion
Company · Champaign · United States

Vanquish Oncology (United States)

Research works
3
▼ 71% vs 2018-21
Citations
11
3.9 per fractional work
Top-10% rate
12.2%
all institutions 10.0%
Open access
26%
world 40%
International
5%
world 18%

Not ranked overall: Vanquish Oncology (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Vanquish Oncology (United States) work in?

In all years, 55% of research at Vanquish Oncology (United States) is in Health Sciences, 45% in Life Sciences. Its largest fields are Medicine (55%), Biochemistry, Genetics and Molecular Biology (45%). It does 1.3× the world's share of Health Sciences.

Life Sciences45%Health Sciences55%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 2 domains and 2 fields, with their numbers
    1. Medicine255.2%
    1. Biochemistry, Genetics and Molecular Biology144.8%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Vanquish Oncology (United States)?

The most cited paper from Vanquish Oncology (United States) is "Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies" (Oana Cristina Danciu, Matthias Holdhoff, Richard A. Peterson et al., 2022), with 30 citations. Next come "The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma" (8) and "Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas" (7).

Most cited papers
#PaperReleasedCitations
1 Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies Oana Cristina Danciu, Matthias Holdhoff, Richard A. Peterson et al. · British Journal of Cancer Open access 5 Dec 2022 30
2 The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma Matthew W. Boudreau, Emily J. Tonogai, Claire P. Schane et al. · Melanoma Research Open access 22 Sep 2023 8
3 Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas Matthias Holdhoff, Martin Kelly Nicholas, Richard A. Peterson et al. · Neuro-Oncology Advances Open access 2023 7
All 3 most cited papers, with filters and sorting

Which research topics does Vanquish Oncology (United States) publish most on?

By volume in 2022-now: Neuroendocrine Tumor Research Advances, Protein Kinase Regulation and GTPase Signaling, Cell death mechanisms and regulation and Glioma Diagnosis and Treatment.

  1. 1 Neuroendocrine Tumor Research Advances Epidemiology 0 works
  2. 2 Protein Kinase Regulation and GTPase Signaling Molecular Biology 0 works
  3. 3 Cell death mechanisms and regulation Molecular Biology 0 works
  4. 4 Glioma Diagnosis and Treatment Genetics 0 works
  5. 5 PARP inhibition in cancer therapy Oncology 0 works
  6. 6 Cancer-related Molecular Pathways Oncology 0 works
  7. 7 Multiple Myeloma Research and Treatments Hematology 0 works
  8. 8 Ocular Oncology and Treatments Ophthalmology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available26.3%not open73.7%

World: 40% of research is openly available.

with international co-authors5.1%domestic only94.9%

World: 18% is written across borders.

How has Vanquish Oncology (United States)'s research output changed?

Output in 2022-2025 was 71% lower than in 2018-2021.

2020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Champaign

All research institutions in Champaign

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Vanquish Oncology (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.